Denny’s board unanimously approved the deal, which values Denny’s at $620 million including debt. Denny’s will be purchased ...

Amgen’s (AMGN) earnings are expected to decline in the third quarter, which is scheduled for November 4, after markets close.

Investors in the therapeutics segment have had steady hands going into earnings, with share prices flat over the last month. Amgen is up 1.3% during the ... fast-growing enterprise software stock that ...

iShares Biotechnology ETF (IBB) offers targeted exposure to the U.S. biotechnology sector, providing investors with access to ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

The S&P 500 VIX futures spiked over 5%. ・The economic calendar of the day is empty due to the ongoing government shutdown. ・AMD’s earnings could serve as a litmus test for the health of the tech ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Amgen, and Biogen. BridgeBio Pharma has an analyst consensus of Strong Buy, with a price target consensus of $78.40, implying a 23.72% upside from current levels. In a report released yesterday, H.C.

The new lawsuit argues that the board’s action conflicted with federal patent laws by not allowing the company to charge as much as it wants.

Novo Nordisk NVO is scheduled to report its third-quarter 2025 results before the opening bell on Nov. 5, 2025. The Zacks ...

British Pound US Dollar, US Dollar Japanese Yen, US Dollar Swiss Franc, Nasdaq 100. Read 's Market Analysis on Investing.com ...

Markets this week focus on Fed commentary, AI earnings, and private jobs data as investors assess rate-cut prospects and the impact of the prolonged shutdown.